Biopharma Team

Ron wooten
Founding Partner

Ron Wooten, Founding Partner, of NovaQuest has over 25 years of healthcare investing experience is currently the CIO of NovaQuest Capital Management. He also heads the investment committee of the General Partner of NovaQuest Pharma Opportunities Fund III and IV. His responsibilities include management company oversight, investment policy, fundraising, and the day-to-day management of the NovaQuest Pharma Opportunities business.

Since its formation in 2000 through November 2010, while NQ was a business unit within Quintiles; Mr. Wooten led the platform in creating and managing unique relationships, structured finance and equity investments with more than $2 billion in gross commitments, capital or services to companies of all sizes. He was also an Executive Vice President of Quintiles and managed their customer-partnering arrangements worldwide. He also served on the Quintiles Board of Directors from January 2008 through November 2010.

Mr. Wooten’s previous experience includes nine years with First Union Securities, where he served as a Managing Director of Investment Banking focusing on M&A transactions across the middle market. Before he started his career in finance, he was a member of the New England Patriots football team from 1981 to 1990.

Mr. Wooten received his Bachelor’s degree in Chemistry from the University of North Carolina at Chapel Hill and earned an MBA from Boston University.

JOHN BRADLEY
Founding Partner

John Bradley, Founding Partner, has nearly 20 years of experience in the healthcare industry and 30 years of overall experience in finance. He served as Senior Vice President of the NovaQuest business unit of Quintiles. Mr. Bradley negotiated and complex structured transactions, managed asset portfolios and directed the day-to-day finances of NovaQuest. As Senior Vice President of Quintiles’ Corporate Development Group, he directed a number of strategic transactions in acquisitions, divestitures, joint ventures, strategic sourcing and debt issuances.

Prior to joining Quintiles in 1996 as a Vice President of Finance, Mr. Bradley led several smaller companies as Chief Financial Officer. He began his career as an analyst for Conoco, and held finance and area controller positions for RJR Nabisco and Ryder Systems.

Mr. Bradley earned a Bachelor’s degree in Business Administration and an MBA from Wake Forest University, and is licensed as a Certified Public Accountant in the State of North Carolina.

WILLIAM ROBB
Founding Partner

William Robb, Founding Partner, is a member of the investment committee of the General Partner of NovaQuest Pharma Opportunities Fund III and IV. He has over 20 years of experience in the global healthcare industry. From the formation of the NovaQuest unit at Quintiles in 2000 through 2010, Mr. Robb led or had material involvement in the structuring, negotiation and management of over $1.4 billion in product-based and company investments. These included investment commitments of between $30m – $450m into both private and global biopharmaceutical companies, and in many cases, investment syndicates.

From 1997–2000, Mr. Robb led strategic consulting engagements for multiple healthcare industry clients at The Wilkerson Group in New York. His previous experience also includes business strategy consulting for A.T. Kearney and the management of World Bank global development projects.

He graduated with honors from Princeton University and holds an MBA in finance and strategy from the Kellogg Graduate School of Management at Northwestern University.

JONATHAN TUNNICLIFFE
Founding Partner

Jonathan Tunnicliffe, Founding Partner, is a member of the investment committee of the General Partner of NovaQuest Pharma Opportunities Fund III and IV. He has over 25 years of experience in the global healthcare industry. From the formation of the NovaQuest unit at Quintiles in 2000 through 2010, Mr. Tunnicliffe led the due diligence for over $1.4 billion in product-based and company investments. These transactions ranged from $30m – $450m commitments to both private and leading public biopharmaceutical companies.

Mr. Tunnicliffe was previously a founding member and Director of Operations of a specialized clinical research organization, S-Cubed, where he led all operational functions. In Mr. Tunnicliffe’s earlier career, he was a medical statistician at SmithKline and French (now Glaxo SmithKline) and at the University of Sheffield.

Mr. Tunnicliffe has a Bachelor’s degree in Mathematical Statistics from the University of Liverpool, a Master of Science in Medical Statistics from the University of Newcastle-upon-Tyne and an MBA from Sheffield Hallam University.

MICHAEL BOLOGNA
Partner

Michael Bologna, Partner, is involved in the due diligence, structuring and negotiating of investments in the Biopharmaceutical industry. Prior to joining NovaQuest, upon its formation in 2010, Mr. Bologna served three years as a transaction/due diligence leader for the NovaQuest unit at Quintiles. Mr. Bologna had material involvement in the structuring, negotiation and management of a wide variety of product-based and company investments.

Prior to joining NovaQuest, Mr. Bologna served in marketing and business development roles with EMD Pharmaceuticals (U.S. subsidiary of Merck KGaA). He was also with Eli Lilly and Company as part of the Global Oncology team.

Mr. Bologna earned a Bachelor’s of Science degree in Nursing from University of Michigan and holds an MBA from Fuqua School of Business at Duke University.

MATT BULLARD
Partner

Matt Bullard, Partner, has over 15 years of experience investing in the healthcare industry. His role at NovaQuest involves developing, structuring and negotiating investments in the healthcare industry. From the formation of the NovaQuest business unit at Quintiles through 2010, Mr. Bullard served as the Head of Investment Analytics. In this role, he was responsible for pricing, financial modeling, structuring and negotiating the NovaQuest business unit’s product-based and company investments with a variety of biopharmaceutical companies. Mr. Bullard also played a material role in committing greater than $1.4 billion in gross capital to the NovaQuest business unit’s investment transactions.

Prior to joining Quintiles, Mr. Bullard was a Financial Analyst with Jefferson Pilot Financial in North Carolina.

He earned a Bachelor’s of Science degree in Accounting from the University of North Carolina at Greensboro and an MBA from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill.

RYAN WOOTEN
Principal

Ryan Wooten, Principal, is responsible for financial modeling, investment due diligence and transaction structuring. Prior to joining NovaQuest, Mr. Wooten worked in investment banking at Citigroup in New York City, where he focused on strategic transactions broadly within the healthcare industry.

Mr. Wooten earned a Bachelor’s of Science degree in Business Administration from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill.

Sunao Nishimura
Principal

Mr. Nishimura joined NovaQuest in October 2015 as Principal on secondment from Mitsui & Co., Ltd.  He has over 15 years of experience in the finance/investment industry where he took instrumental roles in deal sourcing, financial modeling, transaction structuring and negotiation.  He has been Mitsui since 2013 and most recently focused on private equity investments in various industries including healthcare and biopharmaceuticals.  Prior to joining Mitsui, Mr. Nishimura worked as a Vice President at Asia Pacific Land, a real estate private equity firm based in Tokyo.  He was also with Credit Suisse and a boutique risk management consulting firm headquartered in the US.  Mr. Nishimura earned a Bachelor’s and Master’s degree in Civil Engineering / Urban Design from Kyoto University and holds an MBA from INSEAD in France.